Case Study: AggreGuard improves viral kinetics in measles process

Enhancement Potential for a Classical Batch-Mode Upstream Measles Process*: Impact of AggreGuard™

AggreGuard™, a CellRev product, was independently evaluated in a commercially relevant measles vaccine process without altering standard operating protocol, showing:

  • ↓ cell-to-cell adhesion and ↑ cell culture homogeneity.
  • ↓ glucose/glutamine consumption and ↓ lactate/ammonia production.
  • ↑ viral infection kinetics and ↓ time to peak viral titre
  • Up to 8% cost reduction in upstream manufacturing per 1L per day

Download the full report below.

Related Blogs

(Newcastle Upon Tyne, 11th June 2025) The Kuraray Life Innovation Business Promotion Department, a division of Kuraray Co., Ltd. (TYO: 3406), a …

Except for hematopoietic-derived cells, most cells isolated from animals are naturally adherent. In vivo, adherent cells interact with their surrounding environment and …

CellRev launches its proprietary media additive AggreGuard™ which prevents aggregation of adherent cells and increases cell yield in existing VERO processes CellRev, …

Share